Wikidata

(Q97045718)

English

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

clinical trial

In more languages

Statements

title
MATCH Treatment Subprotocol P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients With Tumors With PTEN Loss by IHC (English)
0 references
medical condition
lymphoma
0 references
multiple myeloma
0 references
start time
25 February 2016
0 references
end time
7 June 2018
0 references
number of participants
35
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q97045718&oldid=1893121862"